December 15, 2023 06:47 AM ESTUpdated 10:45 AM

Reneo’s PhIIb rare disease trial failure forces layoffs, cost cuts — stock plummets

Ayisha Sharma

News Reporter

Reneo Pharmaceuticals’ stock plunged by 82% as it revealed plans to slash 70% of its workforce after its only drug candidate disappointed in a registrational …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Reneo’s PhIIb rare disease trial failure forces layoffs, cost cuts — stock plummets

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Re­neo’s PhI­Ib rare dis­ease tri­al fail­ure forces lay­offs, cost cuts — stock plum­mets

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Reneo’s PhIIb rare disease trial failure forces layoffs, cost cuts — stock plummets

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?